Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
Daniel PietraszShufang Wang-RenaultGilles ManceauLaetitia DahanMathilde PostelJerome Durand-LabrunieKarine Le MalicotClaire MulotYves RinaldiJean-Marc PhelipSolene DoatHélène BlonsAurelien de ReyniesJean-Baptiste BachetValérie TalyPierre Laurent-PuigPublished in: British journal of cancer (2021)
In this first ctDNA assessment in a large series of mPDAC derived from clinical trials, ctDNA was detectable in 56.8% of patients and confirmed as an independent prognostic marker.